[PDF][PDF] MONARCH 3: abemaciclib as initial therapy for advanced breast cancer

MP Goetz, M Toi, M Campone, J Sohn… - J clin …, 2017 - sbmastologia.com.br
MP Goetz, M Toi, M Campone, J Sohn, S Paluch-Shimon, J Huober, IH Park, O Trédan…
J clin oncol, 2017sbmastologia.com.br
Purpose Abemaciclib, a cyclin-dependent kinase 4 and 6 inhibitor, demonstrated efficacy as
monotherapy and in combination with fulvestrant in women with hormone receptor (HR)–
positive, human epidermal growth factor receptor 2 (HER2)–negative advanced breast
cancer previously treated with endocrine therapy.
Purpose
Abemaciclib, a cyclin-dependent kinase 4 and 6 inhibitor, demonstrated efficacy as monotherapy and in combination with fulvestrant in women with hormone receptor (HR)–positive, human epidermal growth factor receptor 2 (HER2)–negative advanced breast cancer previously treated with endocrine therapy.
sbmastologia.com.br